Equasens SA EQS

PRESS RELEASE H1 2026 results: well-managed growth and improved profitability H1 2026 revenue of €124.5m (+7.3%): growth driven by the Erevo acquisition and the integration of Novaprove and the DIS business, up 1.4% like-for-likeAnnual recurring revenue (ARR) of €111.1m at June 30, 2026, +8.8%, with a strong organic componentCurrent EBITDA of €33.3m (+11.9%), with the EBITDA margin increasing to 26.8% from 25.7% in H1 2025Current operating income of €23.7m (+11.9%): the current operating margin

Equasens Activates the Business Continuity Plan for its subsidiary ASCA in Chessy (France,77) Villers-lès-Nancy, September 22, 2026, 5:45 p.m. CEST – Equasens (ISIN: FR0012882389 – Ticker: EQS), a leader in digital healthcare solutions, announces that the headquarters and warehouse of its subsidiary ASCA, a specialist in the deployment of electronic labeling solutions for pharmacies, were affected by a fire, the source of which has now been extinguished. ASCA, a subsidiary of the Equasens Group,

Strong growth in maintenance and subscriptions revenue (+8.4% to €55.7 million), including solid organic growth (+4.7%) in H1 2026 Positive momentum in the French Pharmacy business, driven in particular by software innovations and services (+4.3% in H1 2026), and in Italy, supported by growth in the customer base and new hardware solutions (+42.4% in H1 2026) Successful launch of the new digital training offering (virtual classrooms) introduced by the MEDICAL SOLUTIONS Division Villers-lès-Nancy

As European markets navigate the challenges of geopolitical tensions and inflationary pressures, investors continue to seek stability and growth through dividend stocks. In such a climate, selecting stocks with robust earnings growth and consistent dividend payouts can be an effective strategy for those looking to generate income while potentially mitigating volatility.

Villers-lès-Nancy, 29 April 2026 - 6:00 PM (CEST) PRESS RELEASE Solid Q1 2026 performance: revenue of €61.4 million(+7.7% reported) Continued momentum in the PHARMAGEST and AXIGATE LINK divisionsSuccessful integration of EREVO within the Medical Solutions division Initial revenue contribution from the SÉGUR Wave 2 programme At 31 March 2026, Equasens Group (Euronext Paris™ - Compartment B - FR 0012882389 -EQS), a leading provider of digital solutions for healthcare professionals, reported revenu

Villers-lès-Nancy, 30 March 2026 - 08:00 (CEST) PRESS RELEASE 2025 annual resultsEquasens reports a solid performanceacross all financial indicators FY 2025 revenue of €236.5 million (+9.1%): continued strong performance driven by a portfolio of innovative solutions for healthcare professionals and providers Annual Recurring Revenue (ARR) up sharply: €108.0 million at December 31, 2025, representing 8.8% growth versus 2024 EBITDA of €66.7 million (+9.1%), highlighting effective cost control in a